NCT00401401

Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer

An Open-labeled Trial With a Dose-escalation Part and a Parallel Group Design(1) Investigating Zalutumumab, an Anti-EGF Receptor Antibody, in Combination With Chemo-Radiation as First Line Treatment of Patients With Cancer of the Head and Neck (1) The Parallel Group Part Was Cancelled

• Status: Terminated
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Genmab · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to investigate the safety of zalutumumab in combination with chemotherapy and radiotherapy as treatment of patients with head and neck cancer

Conditions

• Head and Neck Cancer
• Squamous Cell Cancer

Interventions

Type	Name	Description
DRUG	zalutumumab	Eight weekly infusions
DRUG	cisplatin	Infusions
PROCEDURE	Radiotherapy	Daily in the treatment period

Timeline

• Start date: 2006-12-01
• Primary completion: 2010-10-01
• Completion: 2010-10-01
• First posted: 2006-11-20
• Last updated: 2011-12-23
• Results posted: 2011-12-23

Locations

7 sites across 5 countries: United States, Belgium, France, Netherlands, Sweden